New Matter: Inside the Minds of SLAS Scientists

More Complex Cultures

April 04, 2022 SLAS Episode 103
New Matter: Inside the Minds of SLAS Scientists
More Complex Cultures
Show Notes

In this first podcast of our series on new technologies, we welcomed back Iscaffpharma by chatting with Per Setterberg, CEO and  Professor Göran Landberg, CMO.  Göran talks to us about how pre-clinical testing in human tumor microenvironment  and synthetic copies of the same adds value to drug screening of oncology drugs. The model creates a pre-clinical fingerprint that mimics the potential effect a drug will have in humans, as well as reduces the need for animal models. Dive in with us as we go in depth into the use of 3D printed scaffolds in cancer drug screening, the ethical considerations behind removing the use of animal models, and what future advances they see in using their technology. 

Iscaffpharma  is a Bio-Tech company focusing on developing better treatments of aggressive cancers. To learn more about their research and work, check out their publications here

SLAS 2022 Americas Sample Management Symposium

  • September 15-16, 2022
  • La Jolla, CA, USA

SLAS 2022 AI Data Pipelines for Life Sciences Symposium

  • September 26-27, 2022
  • Seattle, WA, USA

SLAS 2022 Bio Entrepreneurship Symposium

  • 27-28 October 2022
  • Brussels, Belgium

The SLAS 2022 Americas Sample Management Symposium program is next month in La Jolla, CA!
Register by visiting: https://www.slas.org/events-calendar/slas-2022-americas-sample-management-symposium/attend/register/